Introduction
The measurement of prostate speci®c antigen (PSA) has modi®ed the diagnosis and follow-up of prostate cancer. Localised prostate cancer is commonly treated by either radiotherapy or radical prostatectomy but there is still no evidence showing the superiority of either treatment in preventing tumor recurrence and progression. A raised serum PSA level may be associated with prostatic hypertrophy andaor prostate cancer. 1, 2 After prostate irradiation PSA does not become undetectable because prostate tissue is still present and remains capable of producing PSA. The interpretation of post-irradiation serum PSA values is therefore not straightforward. Following radiation therapy for early prostate cancer serum PSA levels progressively decrease. After treatment the median time required to reach the nadir in PSA levels is 18 months. 3 A rising PSA after irradiation is associated with progression to metastatic disease. 4 After radical prostatectomy, potential complete remission is associated with undectable levels of PSA. Most men with local or distant recurrence following surgery have detectable serum PSA. 5 ± 10 In this study, serial PSA measurements during followup were analysed, and the biochemical free survivals were studied.
Patients and methods
Of the 180 consecutive cases in our department from 1987 ± 1993. 100 patients had undergone radical retropubic prostatectomy and 80 patients had undergone external beam radiotherapy for localised prostate cancer. Patients who had undergone hormonal treatment, who showed evidence of extracapsular spread or for whom complete follow up data were not available were excluded from the study (n 75).
One hundred and ®ve patients with clinical T1-T2N0MO tumors were retrospectively included in this study: Forty-®ve had undergone external beam radiotherapy and 60 a radical prostatectomy. All patients had a complete diagnostic work up including radioisotope bone scan and a computerised tomography scan. Serum PSA (ngaml) was measured before treatment, six months after surgery or radiotherapy and yearly thereafter.
Mean length of follow up was 53.26 AE 25 month in radiotherapy patients and 62.63 AE 25 month in surgical patients (ns).
The choice of treatment followed the decision of the patient after discussion with his urologist, family doctor and radotherapist.
In the surgical group a PSA level above 0.005 ngaml was considered as evidence of disease progression.
In the radiotherapy group disease progression was de®ned as an increase in PSA b 1 ngaml above its lowest post treatment level, 1 y after treatment.
Data were analysed using BIcLOGINSERM 1979 ± 1987 software. Survival curves were constructed with the Kaplan ± Meyer method, disease progression and death were the censored events taken into account. The Mantel ± Cox test was used to compare the curves in the two groups.
As measured PSA levels did not follow a normal distribution, central tendencies of PSA values were described in terms of median and range. Variables following a normal distribution were described in terms of mean AE s.d. The Mann and Whitney non parametric test was used to compare quantitative values between the two groups. Qualitative values were compared by the w 2 test.
Results
Median PSA level before treatment was 21 (range 118 ± 47) for the radiotherapy group and 16 (11 ± 31) for the radical prostatectomy group. Mean age was 68.9 AE 5.3 for patients undergoing radiotherapy and 64.9 AE 5.6 for the surgical patients (P`0.01). The Gleason score was higher in patients who had surgery as compared to those with radiotherapy. (Table 3 ). In the surgical group, there was no signi®cant difference between the Gleason score derived from prostate biopsy and that found on the surgical specimen.
There was no statistically signi®cant difference in overall survival rates between the two groups: mean survival was 102 AE 4.56 month (93 ± 111) days in the surgical group and 86.8 AE 350 month (80 ± 937) in the radiotherapy group.
Five patients died in the radiotherapy group: three were related to prostate cancer progression, one was due to myocardial infarction and one to pulmonary tuberculosis.
Eight patients died in the surgical group: six from prostate cancer progression, one from cirrhosis of the liver and one from rectal cancer ( Table 4 and Table 2 ).
Mean time to cancer relapse following treatment was 65 AE 4.89 month (55.4 ± 74.5) for radiotherapy and 67.1 AE 5.62 month (561 ± 781) for surgery (ns). The actariel rates of biochemical free survival was sixty percent at ®ve years in the prostatectomy group and 62% in the radiotherapy group. The difference is not statistically signi®-cant ( Figure 1) .
Analysis of the evolution of median PSA level shows a progressive decline during the ®rst 4 y after radiotherapy. Four years after treatment PSA levels become comparable in the two groups (Table 1) .
Discussion
PSA measurement has modi®ed prostate cancer diagnosis and follow-up particularly in patients with localised disease.
PSA becomes undetectable after radical prostatectomy and its increase is a sign of local or metastatic disease progression. 5 ± 8 The incidence of positive surgical margins ranges from 8 ± 48% in most published series. 11 ± 13 50 ± 70% of patients with positive surgical margins present with increased PSA 4 y following surgery 14 . In our study, 23% of patients treated with radical prostatectomy were found to have positive surgical margins and this could in part account for the biochemical progression observed in this group of patients.
After radiotherapy PSA levels decline progressively reaching lowest levels on average 1 y. An increase from this level is associated with disease progression. 15 ± 18 In our radiotherapy group, biochemical free survival at 5 y was comparable between a PSA nadir 1 y after the end of treatment of`1 ngaml or`4 ngaml. In contrast, there was a statistically signi®cant difference in biochemical free survival At 5 y between PSA nadir`4 ngaml and b 4 ngaml (P`0.00001), Figure 2 .
The choice of treatment for localised prostate cancer is still controversial due to the lack of properly randomised clinical trials comparing radiotherapy to radical prostatectomy. In published series the biochemical free survival rate varies from 65 ± 87% after radical prostatectomy 11,19 ± 23 and from 53 ± 84% after radiotherapy. 24 ± 28 A recent retrospective study on 551 patients with T1 and T2 tumors compared radiotherapy to radical prostatectomy 1 : The overall biological free survival rate at 5 y was 43% for radiotherapy and 57% for radical prostatectomy; the biochemical free survival rate at 5 y was 80% in low risk patients (PSA`10 and Gleason`6) with either treatment modality; in high risk patients (PSA b 10 and Gleason b 6), the biochemical free survival was 26% at 5 y in radiotherapy group and 37% in prostatectomy group.
In a recent retrospective study, D'Amico et al 29 report no statistical difference in the 2 y PSA failure-free survival for potentially curable patients managed de®nitively with surgery or radiation therapy when a comparison stratifying for the pretreatment PSA and biopsy Gleason was performed. Figure 1 The Biochemical free survival after radiotherapy and prostatectomy, at 5 y, the difference was not signi®cant (Kaplan ± Mayer). Figure 2 The Biochemical free survival was completed with the Nadir PSA at 1 y after radiotherapy.
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Conclusion
In our study we compared serial PSA measurements after either treatment: PSA becomes undetectable immediately after radical prostatectomy while it decreases slowly after radiotherapy. During the ®rst year after treatment we found a signi®cant difference in median PSA level between the two groups of patients but this difference decreased progressively during the second and third year and disappeared in the fourth year. PSA is an effective marker of tumour progression after surgery or radiotherapy for localised prostate cancer. In our retrospective study recurrence rates at 5 y were not signi®cant but direct comparisons are limited due to the Gleason score of the two groups.
Prospective randomised clinical trials with a longer follow-up will be required to properly evaluate the long term results of these treatment modalities. 
